Drug intelligence / Profile preview

amorphophallus konjac + garcinia cambogia

Development stage: Preclinical
Administration: Oral

Overview

A combination of standardized extracts from Amorphophallus konjac (containing glucomannan) and Garcinia cambogia (containing hydroxycitric acid). Glucomannan is a water-soluble dietary fiber that may reduce dietary fat absorption, while hydroxycitric acid is a competitive blocker of ATP-citrate-lyase that potentially inhibits fatty acid biosynthesis. This combination has been studied primarily for its effects on weight management and cholesterol levels.

Targets

ACLY (ATP-citrate synthase)

Beyond the preview

Go deeper on amorphophallus konjac + garcinia cambogia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amorphophallus konjac + garcinia cambogia.

Explore the full profile